- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CStone Pharmaceuticals (2616)
The CStone share price today is 5.75, view HK 2616 stock exchange data. Track the latest CStone share price with real-time updates on 2616 stock performance including market cap, day range, 52-week range and dividend yield. Access 2616 charts, earnings dates and analyst estimates to support your investment decisions.
Hong Kong
Currency in HKD
5.75
-0.04(-0.69%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.61
5.95
52 wk Range
4.01
13.15
2616 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.615.95
52 wk Range
4.0113.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2616 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
14.35
Upside
+149.55%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 14.35
(+149.55% Upside)
Earnings
Latest Release
26-03-2026
EPS / Forecast
-0.11 / --
Revenue / Forecast
220.13M / --
Compare 2616 to Peers and Sector
Metrics to compare | 2616 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2616PeersSector | |
|---|---|---|---|---|
P/E Ratio | −18.2x | −8.9x | −0.4x | |
PEG Ratio | 0.05 | 0.11 | 0.00 | |
Price/Book | 12.9x | 7.1x | 2.6x | |
Price / LTM Sales | 29.5x | 10.9x | 3.1x | |
Upside (Analyst Target) | 141.9% | 33.9% | 48.4% | |
Fair Value Upside | Unlock | −2.1% | 6.5% | Unlock |
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the CStone (2616) Share Price Today?
The CStone share price today is 5.75.
What is the current CStone (2616) share price and day range?
As of 14-08-2026, the CStone share price is 5.75, with a previous close of 5.79. The share price has ranged from 5.61 to 5.95 today, while the 52-week range spans from 4.01 to 13.15.
What Is the CStone Market Cap?
As of today, CStone market cap is 9.25B.
What Is the CStone (2616) Share Price Target?
The average 12-month share price target for CStone is 14.35, with a high estimate of 20.08377938 and a low estimate of 9.48452409. 4 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +149.55% Upside potential.
What Is CStone's Earnings Per Share (TTM)?
The CStone EPS (TTM) is -0.31.
From a Technical Analysis Perspective, Is 2616 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does CStone Trade On?
CStone is listed and trades on the Hong Kong Stock Exchange.
What Is the Stock Symbol for CStone?
The stock symbol for CStone is "2616."
How Many Times Has CStone Stock Split?
CStone has split 0 times.
How Many Employees Does CStone Have?
CStone has 136 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.